Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the clinical evidence actually says about comparing these two medicines at this stage of treatment
The biggest misconception: that 10mg Mounjaro maps onto a Wegovy dose
Most people searching for a conversion are looking for a clean equivalence table — something like "10mg Mounjaro equals 1.7mg Wegovy". That table doesn't exist in the clinical literature, and any source claiming it does is guessing. The confusion is understandable. Both medicines reduce appetite and slow gastric emptying, and both are measured in milligrams, so the assumption that their scales overlap is easy to make.
The reality is structural. Tirzepatide (Mounjaro) activates two gut-hormone receptors, GIP and GLP-1. Semaglutide (Wegovy) works on GLP-1 alone. Because the pharmacological targets differ, the doses cannot be translated directly, a 10mg tirzepatide dose and a 2.4mg semaglutide dose are built on entirely different scales. Our page on how Wegovy and Mounjaro doses compare goes deeper into the mechanism behind this.
What the evidence does give us is a head-to-head outcome. In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity. That comparison was at the highest doses of each medicine, not at 10mg specifically. For anyone at 10mg Mounjaro and considering a move to Wegovy, if you have been wondering whether there is a Wegovy equivalent to Mounjaro 10mg, the honest answer is that the question is less about matching doses and more about why the switch is being considered in the first place.
What 10mg Mounjaro and Wegovy's dose range actually represent
Mounjaro is prescribed in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg. Treatment starts at 2.5mg because the body needs time to settle with a new medicine. The starter dose is there to reduce early nausea, not to produce weight loss. By the time someone reaches 10mg they are in the upper-middle of the schedule, typically having titrated over several months. The prescriber's goal from here is usually to continue towards 12.5mg or 15mg if the medicine is well-tolerated and weight loss is progressing.
Wegovy's schedule runs differently: 0.25mg, 0.5mg, 1.0mg, 1.7mg and up to 2.4mg as the standard maintenance dose, with the newer 7.2mg option approved by the MHRA in April 2026 for eligible patients. Those numbers are smaller because semaglutide is active at a different concentration, the scales are simply not comparable. Our detailed page on the Mounjaro to Wegovy dose conversion question sets out the full context for anyone working through this.
NHS England's guidance on weight management injections covers both medicines factually and is worth reading alongside any clinical conversation about switching.
Comparing the two at this treatment stage: a factual overview
The table below summarises key factual differences relevant to someone currently on 10mg Mounjaro who is weighing up Wegovy.
| Factor | Mounjaro (tirzepatide) at 10mg | Wegovy (semaglutide) at maintenance |
|---|---|---|
| Receptor pathway | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Position in dose schedule | Upper-middle (of six steps) | Near or at maximum (2.4mg or 7.2mg) |
| Average trial weight loss at highest dose | ~20–21% at 15mg (SURMOUNT-1, NEJM) | ~15% at 2.4mg (STEP 1, NEJM); ~20.7% at 7.2mg |
| Administration | Once-weekly subcutaneous injection, KwikPen | Once-weekly subcutaneous injection, pre-filled pen |
| NICE recommendation | TA1026 (BMI ≥35 + ≥1 comorbidity (private: BMI ≥30 or ≥27 + condition) | TA875) BMI ≥35 + ≥1 comorbidity, max 2 years in specialist service |
| Black Triangle status | Yes (additional MHRA monitoring | Yes) additional MHRA monitoring |
The STEP 1 trial results are published by the New England Journal of Medicine and are the basis for Wegovy's licensed weight-loss evidence. For a fuller side-by-side look at the two medicines, our Wegovy vs Mounjaro comparison covers efficacy, side effects and eligibility in one place.
When switching actually makes clinical sense, and what happens next
There are legitimate reasons a prescriber might discuss moving from Mounjaro to Wegovy. Supply interruptions, tolerability differences, a patient's preference for avoiding the dual-pathway effects, or a change in clinical circumstances can all come into the conversation. What switching is not is a straightforward dose step: a prescriber needs to decide whether to restart Wegovy from its lowest dose or, in some cases, move to a dose that reflects existing tolerance, and our page exploring whether 1mg Wegovy is the same as 10mg Mounjaro explains clearly why that judgement cannot be made from a conversion chart.
The side-effect profiles of the two medicines overlap heavily. Both commonly cause nausea, diarrhoea, constipation and fatigue, particularly around dose changes. The MHRA published a Drug Safety Update in January 2026 noting acute pancreatitis as an infrequent but serious known risk across GLP-1 medicines, severe stomach pain reaching the back warrants urgent medical attention. Reporting any unexpected side effects through the Yellow Card scheme supports ongoing safety monitoring for both treatments.
At nume, sorry, at... no: at nume, a prescriber personally reviews every transfer case. If you are currently on 10mg Mounjaro and want to explore whether Wegovy is appropriate, our prescribers look at your full clinical picture before recommending anything. You can see more about the clinical team behind those decisions on our clinical oversight page. For a closer look at the specific dose equivalence question, our page on 2.4mg Wegovy versus 10mg Mounjaro addresses that comparison directly. Which medicine suits you is a clinical decision our prescribers make with you, not something any conversion guide can settle.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.